Page last updated: 2024-10-28

hypericin and Acute Confusional Senile Dementia

hypericin has been researched along with Acute Confusional Senile Dementia in 2 studies

Research Excerpts

ExcerptRelevanceReference
"Pretreatment with hypericin (5 μM and 15 μM) significantly suppresses oligomeric Aβ42 (oAβ42)-induced expression of interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor α (TNF α) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity."5.43Hypericin inhibits oligomeric amyloid β42-induced inflammation response in microglia and ameliorates cognitive deficits in an amyloid β injection mouse model of Alzheimer's disease by suppressing MKL1. ( Li, P; Qian, F; Wang, Y; Xu, X; Zhang, M, 2016)
"Alzheimer's disease (AD) and type 2 diabetes (T2D) are two of the most common diseases in elderly population and they have a high rate of comorbidity."1.91Hypericin as a potential drug for treating Alzheimer's disease and type 2 diabetes with a view to drug repositioning. ( Gao, LH; Ma, QH; Wang, J; Yan, F; Yuan, X, 2023)
"Pretreatment with hypericin (5 μM and 15 μM) significantly suppresses oligomeric Aβ42 (oAβ42)-induced expression of interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor α (TNF α) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity."1.43Hypericin inhibits oligomeric amyloid β42-induced inflammation response in microglia and ameliorates cognitive deficits in an amyloid β injection mouse model of Alzheimer's disease by suppressing MKL1. ( Li, P; Qian, F; Wang, Y; Xu, X; Zhang, M, 2016)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Yuan, X1
Yan, F1
Gao, LH1
Ma, QH1
Wang, J1
Zhang, M1
Wang, Y1
Qian, F1
Li, P1
Xu, X1

Other Studies

2 other studies available for hypericin and Acute Confusional Senile Dementia

ArticleYear
Hypericin as a potential drug for treating Alzheimer's disease and type 2 diabetes with a view to drug repositioning.
    CNS neuroscience & therapeutics, 2023, Volume: 29, Issue:11

    Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Diabetes Mellitus, Type 2; Drug Repositioning; Human

2023
Hypericin inhibits oligomeric amyloid β42-induced inflammation response in microglia and ameliorates cognitive deficits in an amyloid β injection mouse model of Alzheimer's disease by suppressing MKL1.
    Biochemical and biophysical research communications, 2016, Dec-02, Volume: 481, Issue:1-2

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anthracenes; Cell Line; Cognition; Cognition Diso

2016